Novel oral carbapenem for the treatment of multi-drug resistant pathogens
Iterum is a clinical stage company developing a novel oral carbapenem, sulopenem, for the treatment of serious hospital and community-acquired infections including complicated urinary tract infections, uncomplicated urinary tract infections and complicated intra-abdominal infections.
CEO Corey Fishman
Advent Contact Shahzad Malik
